Clinical Trials Logo

Filter by:
NCT ID: NCT03200444 Recruiting - Stoma Ileostomy Clinical Trials

Evaluation of the Peel Force of New Adhesives From the Skin

Start date: June 26, 2017
Phase: N/A
Study type: Interventional

This study investigates the impact and adhesion of new adhesives to the skin.

NCT ID: NCT03200431 Not yet recruiting - Ileostomy - Stoma Clinical Trials

Evaluation of the Influence of Output on Skin Wearing a New Adhesive

Start date: June 26, 2017
Phase: N/A
Study type: Interventional

The purpose is to investigate the impact real output has on the peristomal skin covered by a newly developed adhesive.

NCT ID: NCT03200418 Recruiting - Ileostomy - Stoma Clinical Trials

Evaluation of the Effect of Output on Newly Developed Adhesives

Start date: June 19, 2017
Phase: N/A
Study type: Interventional

The study investigates the impact real output has on the adhesion of the adhesives.

NCT ID: NCT03199872 Recruiting - Prostate Cancer Clinical Trials

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Start date: March 30, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

NCT ID: NCT03199768 Recruiting - Delirium Clinical Trials

Delirium in Geriatric Hospital Single-bed and Multibed Rooms

Start date: September 15, 2016
Phase: N/A
Study type: Observational

To investigate whether single-bed rooms can prevent and reduce incidence and duration of delirium compared to multi-bed rooms in elderly patients admitted to a geriatric department. In addition, it is investigated whether single-bed rooms reduce the use of psychotropic drugs, opioids, parenteral medication, fixed guard, falls, hospitalization and discharge to institution among delirious patients. Furthermore, to study if delirium is associated with of re-hospitalization, traumatic fall, institutionalization and death within 30 days, compared to those who do not develop delirium.

NCT ID: NCT03198403 Not yet recruiting - Clinical trials for Total Knee Arthroplasty

The Effect of Popliteal Plexus Block on Pain After Total Knee Arthroplasty

Start date: June 29, 2017
Phase: Phase 4
Study type: Interventional

The study aims to investigate the effect of the Popliteal plexus block (PPB) on postoperative pain after total knee arthroplasty

NCT ID: NCT03197636 Enrolling by invitation - Malignant Melanoma Clinical Trials

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Start date: July 1, 2017
Phase: N/A
Study type: Observational

An observational single center study designed to identify response-related biomarkers of anti-programmed death 1 (PD-1) therapy to advanced melanoma patients and to investigate if vitamin D levels are related to treatment response. 40 patients diagnosed with advanced melanoma will be included. Patients are included at the Department of Oncology, Aarhus University Hospital (AUH). All patients will be treated with Pembrolizumab as a standard procedure at the Department of Oncology. The protocol comprises blood samples at baseline, 3 and 6 weeks after treatment initiation with anti-PD1 therapy and three years of observational follow-up. A total amount of 217 ml blood will be drawn during the study period. The study period is 6 weeks followed by 3 years of follow-up. Medical history, symptoms, response to treatment regarding the RESIST criteria and side affects will be recorded at each visit in both the study period and in follow-up. Biochemical markers will be obtained according to normal procedure during study and follow-up visits. 20 Healthy volunteers (HV) are included, matched by age and gender. Collected blood samples (serum, plasma, peripheral blood mononuclear cells) will be analyzed after the last patient has ended the week 6 visit.

NCT ID: NCT03196947 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

SMR-3184
Start date: June 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Multicentre, open label, uncontrolled, phase I pharmacokinetic study, to determine the Maximum Tolerated Dose (MTD) of APO010 administered intravenously on D1, D8 and D15 followed by a one-week drug rest, in patients with multiple myeloma for who have relapsed or are refractory to 2 (in high-risk patients 1) or more different prior therapies and who have Drug Response Predictor (DRP) for APO010 indicating a higher likelihood for response to APO010. The study will contain an extension phase where the recommended Dose will be tested on additional patients.

NCT ID: NCT03196596 Recruiting - Clinical trials for Aortic Valve Stenosis

Added Value of Patient-specific Computer Simulation in Transcatheter Aortic Valve Implantation (TAVI)

TAVIguide
Start date: May 23, 2017
Phase: N/A
Study type: Observational

Transcatheter aortic valve implantation is increasingly used to treat patients with severe aortic stenosis who are at increased risk for surgical aortic valve replacement and is projected to be the preferred treatment modality. As patient selection and operator experience have improved, it is hypothesised that device-host interactions will play a more dominant role in outcome. This, in combination with the increasing number of valve types and sizes, confronts the physician with the dilemma to choose the valve that best fits the individual patient. This necessitates the availability of pre-procedural computer simulation that is based upon the integration of the patient-specific anatomy, the physical and (bio)mechanical properties of the valve and recipient anatomy derived from in-vitro experiments. Patient-specific computer simulation may improve outcome of TAVI by proposing the valve size that best fits the individual patient. The aim of this study is to assess the added value of patient-specific computer simulation in valve size selection.

NCT ID: NCT03193086 Recruiting - Multiple Sclerosis Clinical Trials

The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients

Start date: January 1, 2017
Phase: N/A
Study type: Observational

The development and progression of multiple sclerosis seem to be driven by concomitant inflammation and, to a less well-defined degree, disturbances in metabolism of individual cells of the human central nervous system as well as changes in the dynamical supply of blood to the brain. These alterations in normal physiology can be quantified by investigating the change in specific parameters over the time course of multiple sclerosis evolution. Amongst these specific parameters, the ability of the so-called blood-brain-barrier to selectively filter nutrients from the blood stream prior to passage into the nervous tissue, is disrupted in multiple sclerosis, and the severity of this deficiency seem to be related to the underlying disease burden. The present study utilises a novel imaging technology in order to monitor changes in the integrity of the blood-brain-barrier over the course of treatment with a biological disease modifying agent known as alemtuzumab. Alemtuzumab is a potent immunosuppressant drug. It is hypothesised that alemtuzumab reverts the deficiency in blood-brain-barrier integrity and, conversely, the severity of blood-brain-barrier disruption at several time points during alemtuzumab treatment can be utilised as prognostic marker for the requirement of additional administration of alemtuzumab beyond the regular treatment regimen. In addition, several other factors are investigated by advanced imaging techniques in combination with blood and urine samples in order to elucidate the possible underlying mechanism of alemtuzumab efficacy. It is hypothesized that alemtuzumab normalises metabolic alterations and changes in the blood supply through resolution of inflammation in the brains of multiple sclerosis patients.